SLSteven J. Lobritto

Steven J. Lobritto

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Steven J. Lobritto has a total of 67 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Analysis of Viral Testing in Nonacetaminophen Pediatric Acute Liver Failure

    by Kathleen B. Schwarz, Dominic Dell Olio, Steven J. Lobritto, M. James Lopez, Norberto Rodriguez‐Baez, Nada A. Yazigi, Steven H. Belle, Song Zhang, Robert H. Squires, Pediatric Acute Liver Failure Study Group

    Objective: Viral infections are often suspected to cause pediatric acute liver failure (PALF), but large‐scale studies have not been performed. We analyzed the results of viral testing among nonacetaminophen PALF study participants.Methods: Participants were enrolled in the PALF registry. Diagnostic evaluation and final diagnosis were determined by the site investigator and methods for viral testing by local standard of care. Viruses were classified as either causative viruses (CVs) or associated viruses (AVs). Supplemental testing for CV was performed if not done clinically and serum was available. Final diagnoses included “viral,” “indeterminate,” and “other.”Results: Of 860 participants, 820 had at least 1 test result for a CV or AV. A positive viral test was found in 166/820 (20.2%) participants and distributed among “viral” (66/80 [82.5%]), “indeterminate” (52/420 [12.4%]), and “other” (48/320 [15.0%]) diagnoses. CVs accounted for 81/166 (48.8%) positive tests. Herpes simplex virus (HSV) was positive in 39/335 (11.6%) who were tested 26/103 (25.2%) and 13/232 (5.6%) among infants 0 to 6 and >6 months, respectively. HSV was not tested in 61.0% and 53% of the overall cohort and those 0 to 6 months, respectively. Supplemental testing yielded 17 positive, including 5 HSV.Conclusions: Viral testing in PALF occurs frequently but is often incomplete. The evidence for acute viral infection was found in 20.2% of those tested for viruses. HSV is an important viral cause for PALF in all age groups. The etiopathogenic role of CV and AV in PALF requires further investigation.


  • Autoantibodies and Autoimmune Disease During Treatment of Children With Chronic Hepatitis C

    by Jean P. Molleston, William Mellman, Michael R. Narkewicz, William F. Balistreri, Regino P. Gonzalez‐Peralta, Maureen M. Jonas, Steven J. Lobritto, Parvathi Mohan, Karen F. Murray, Dolores Njoku, et al.

    Objectives: Autoantibodies were studied in a well‐characterized cohort of children with chronic hepatitis C during treatment with pegylated interferon and ribavirin to assess the relation with treatment and development of autoimmune disease.Methods: A total of 114 children (5–17 years), screened for the presence of high‐titer autoantibodies, were randomized to pegylated interferon with or without ribavirin. Anti‐nuclear, anti‐liver‐kidney‐microsomal, anti‐thyroglobulin, anti‐thyroid peroxidase, insulin, anti‐glutamic acid decarboxylase (GAD) antibodies were measured after trial completion using frozen sera.Results: At baseline, 19% had autoantibodies: anti‐nuclear antibodies (8%), anti‐liver‐kidney‐microsomal antibodies (4%), and glutamic acid decarboxylase antibodies (4%). At 24 and 72 weeks (24 weeks after treatment completion), 23% and 26% had autoantibodies (P = 0.50, 0.48 compared with baseline). One child developed diabetes and 2 hypothyroidism during treatment; none developed autoimmune hepatitis. At 24 weeks, the incidence of flu‐like symptoms, gastrointestinal symptoms, and headaches was 42%, 8% and 19% in those with autoantibodies versus 52%, 17%, and 26% in those without (P = 0.18, 0.36, and 0.20, respectively). In children with negative hepatitis C virus polymerase chain reaction at 24 weeks, there was no difference in the rate of early virologic response/sustained virologic response, respectively, in those with autoantibodies 76%/69% vs 58%/65% in those without (P = 0.48).Conclusions: Despite screening, we found autoantibodies commonly at baseline, during treatment for chronic hepatitis C and after. The presence of antibodies did not correlate with viral response, adverse effects, or autoimmune hepatitis. Neither screening nor archived samples assayed for thyroid and diabetes‐related antibodies identified the 3 subjects who developed overt autoimmune disease, diabetes (1), and hypothyroidism (2).


  • Living-Donor Liver Transplantation: Current Perspective

    by Tomoaki Kato, Jean Emond, Steven Lobritto

    The disparity between the number of available deceased liver donors and the number of patients awaiting transplantation continues to be an ongoing issue predisposing to death on the liver transplant waiting list. Deceased donor shortage strategies including the use of extended donor-criteria deceased donor grafts, split liver transplants, and organs harvested after cardiac death have fallen short of organ demand. Efforts to raise donor awareness are ongoing, but the course has been arduous to date. Living donor transplantation is a means to access an unlimited donor organ supply and offers potential advantages to deceased donation. Donor safety remains paramount demanding improvements and innovations in both the donor and recipient operations to ensure superior outcomes. The specialty operation is best preformed at centers with specific expertise and shuttling of select patients to these centers supported by third party payers is critical. Training future surgeons at centers with this specific experience can help disseminate this technology to improve local availability. Ongoing research in immunosuppression minimization, withdrawal and tolerance induction may make living donation a desired first-line operation rather than a necessary albeit less-desirable option. This chapter summarizes the progress of living liver donation and its potential applications.


  • Open Access

    Intravenous N-acetylcysteine in pediatric patients with nonacetaminophen acute liver failure: A placebo-controlled clinical trial

    by Robert H. Squires, Anil Dhawan, Estella Alonso, Michael R. Narkewicz, Benjamin L. Shneider, Norberto Rodriguez‐Baez, Dominic Dell Olio, Saul Karpen, John Bucuvalas, Steven Lobritto, et al.

    N-acetylcysteine (NAC) was found to improve transplantation-free survival in only those adults with nonacetaminophen (non-APAP) acute liver failure (ALF) and grade 1-2 hepatic encephalopathy (HE). Because non-APAP ALF differs significantly between children and adults, the Pediatric Acute Liver Failure (PALF) Study Group evaluated NAC in non-APAP PALF. Children from birth through age 17 years with non-APAP ALF enrolled in the PALF registry were eligible to enter an adaptively allocated, doubly masked, placebo-controlled trial using a continuous intravenous infusion of NAC (150 mg/kg/day in 5% dextrose in water [D5W]) or placebo (D5W) for up to 7 days. The primary outcome was 1-year survival. Secondary outcomes included liver transplantation-free survival, liver transplantation (LTx), length of intensive care unit (ICU) and hospital stays, organ system failure, and maximum HE score. A total of 184 participants were enrolled in the trial with 92 in each arm. The 1-year survival did not differ significantly ( P = 0.19) between the NAC (73%) and placebo (82%) treatment groups. The 1-year LTx-free survival was significantly lower ( P = 0.03) in those who received NAC (35%) than those who received placebo (53%), particularly, but not significantly so, among those less than 2 years old with HE grade 0-1 (NAC 25%; placebo 60%; P = 0.0493). There were no significant differences between treatment arms for hospital or ICU length of stay, organ systems failing, or highest recorded grade of HE. Conclusion : NAC did not improve 1-year survival in non-APAP PALF. One-year LTx-free survival was significantly lower with NAC, particularly among those


  • A Prospective Clinical Trial Shows That Intravenous N-Acetylcysteine (NAC) Does Not Improve Survival in Pediatric Patients With Non-Acetaminophen Acute Liver Failure

    by Robert Squires, Anil Dhawan, Estella M. Alonso, Michael R. Narkewicz, Norberto Rodriguez-Baez, Deirdre A. Kelly, John Bucuvalas, Saul J. Karpen, Benjamin L. Shneider, Elizabeth B. Rand, et al.


  • S1003 An Analysis of Viral Testing in Non-APAP Pediatric Acute Liver Failure (PALF)

    by Kathleen B. Schwarz, Dominic Dell-Olio, Steven J. Lobritto, M James Lopez, Norberto Rodriquez-Baez, Nada A. Yazigi, Steven H. Belle, Sharon M. Lawlor, Song Zhang, Robert Squires

  • Open Access

    Pharmacokinetics of mycophenolate mofetil in stable pediatric liver transplant recipients receiving mycophenolate mofetil and cyclosporine

    by Steven J. Lobritto, Philip Rosenthal, Rene Bouw, Mimi Leung, Paul Snell, Richard D. Mamelok

    There are few pharmacokinetic data for mycophenolate mofetil (MMF) when used in combination with cyclosporine (CsA) in pediatric liver transplant recipients. The aim of this study was to assess the pharmacokinetics of MMF in stable pediatric liver transplant patients and estimate the dose of MMF required to provide a mycophenolic acid (MPA) exposure similar to that observed in adult liver transplant recipients receiving the recommended dose of MMF (target area under the plasma concentration‐time curve from 0 to 12 hours [AUC0–12] for MPA of 29 μg·hour/mL in the immediate posttransplantation period and 58 μg·hour/mL after 6 months). A 12‐hour pharmacokinetic profile was collected for 8 pediatric patients (mean age 20.9 months) on stable doses of MMF and CsA who had received a liver transplant ≥6 months prior to entry and who had started on MMF within 2 weeks of transplantation. Mean MMF dosage was 285 mg/m2 (range, 200‐424 mg/m2). Of 8 patients, 7 had a MPA AUC0‐12 (range, 11.0‐37.2 μg·hour/mL) well below the target. One patient had an AUC0‐12 ≥58 μg·hour/mL but was considered an outlier and was excluded from analyses. Mean MPA AUC0‐12 and maximum plasma concentration values were 22.7 ± 10.5 μg·hour/mL and 7.23 ± 3.27 μg/mL, respectively; values normalized to 600 mg/m2 (the approved pediatric dose in renal transplantation) were 47.0 ± 21.8 μg·hour/mL and 14.5 ± 4.21 μg/mL. In conclusion, assuming that MPA exhibits linear pharmacokinetics, when used in combination with CsA, a MMF dose of 740 mg/m2 twice daily would be recommended in pediatric liver transplant recipients to achieve MPA exposures similar to those observed in adult liver transplant recipients. This finding should be confirmed by a prospective trial. Liver Transpl 13:1570–1575, 2007. © 2007 AASLD.